Last updated: February 27, 2026
What is the drug associated with NDC 24979-0724?
The drug identified by NDC 24979-0724 is Zirabev (bevacizumab-bvzr), a biosimilar of Avastin (bevacizumab). Approved by the FDA in 2020, it is indicated for various cancers, including metastatic colorectal cancer, non-small cell lung cancer, and glioblastoma.
How does Zirabev fit within the biosimilar and oncology landscape?
Zirabev entered a competitive biosimilar market targeting expensive biologic therapies used in oncology. Its launch follows the expiration of the reference product patent and existing biosimilar entries, notably:
- Avastin (bevacizumab) market launched in 2004.
- Multiple biosimilars introduced since 2018, including Amgen’sMvasi and Samsung Bioepis’ Zirabilis.
- The biosimilar market grew rapidly, with a compounded annual growth rate (CAGR) of approximately 13% from 2018 to 2022 (IQVIA, 2022).
What is the current market size for bevacizumab and Zirabev?
- The global bevacizumab market was valued at nearly $6.48 billion in 2021.
- The U.S. accounted for about 85% of this market, estimated at approximately $5.5 billion in 2022.
- Biosimilars hold a cumulative market share of approximately 40% of the U.S. bevacizumab market by 2022, amounting to roughly $2.2 billion.
Market share distribution (2022):
| Product |
Approximate Market Share |
Revenue (USD) |
| Avastin (reference) |
60% |
$3.3 billion |
| Zirabev (biosimilar) |
20% |
$1.1 billion |
| Other biosimilars |
20% |
$0.9 billion |
Note: Values are approximations based on IQVIA data and market reports.
What are the price trends and projections for Zirabev?
Current pricing
- List price for Zirabev in the U.S. is approximately 25-30% lower than Avastin.
- A standard 400 mg dose based on an average wholesale price (AWP) is priced around $2,500 to $3,000.
Revenue projections
- By 2027, biosimilar market share for bevacizumab is projected to reach 70%, driven by healthcare cost containment and payer incentives.
- Zirabev's market share is expected to approach 25-30% of biosimilar sales within 3 years of widespread adoption.
Price trajectory forecasts
| Year |
Estimated Price per 400 mg Dose (USD) |
Notes |
| 2023 |
$2,500 – $3,000 |
Current; slight volume growth |
| 2024 |
$2,300 – $2,700 |
Volume increases; payer push for lower prices |
| 2025 |
$2,200 – $2,600 |
Cost-driven negotiations; generic substitution becomes more common |
| 2026 |
$2,000 – $2,400 |
Market saturation; competitive pressures |
| 2027 |
$1,900 – $2,200 |
Price stabilization at lower levels |
Drivers influencing prices
- Entry of additional biosimilars increases competition.
- Payer and hospital procurement policies favor lower-cost biologics.
- Patent expiry of reference biologic encourages biosimilar adoption.
- Market penetration strategies by Amgen and other players.
What are the key factors impacting market growth?
- Regulatory pathways: FDA’s accelerated approval protocols facilitate biosimilar entry.
- Market penetration: Physician acceptance influences uptake.
- Pricing pressures: Payer negotiations and formulary placements impact revenues.
- Manufacturing costs: Biosimilar production costs are declining, further pushing down prices.
Key Takeaways
- NDC 24979-0724 corresponds to Zirabev, a biosimilar of Avastin, launched in 2020.
- The U.S. bevacizumab market is valued at approximately $5.5 billion, with biosimilars accounting for 40% of sales.
- Zirabev’s current list price is 25-30% lower than Avastin, with anticipated price declines of 20-25% over the next five years.
- Market share for Zirabev could reach 25-30% of biosimilar sales by 2027, assuming standard competitive and regulatory conditions.
- Payer strategies and biosimilar acceptance remain primary drivers of market dynamics.
5 FAQs
1. How does Zirabev compare to other bevacizumab biosimilars?
It is priced slightly lower than competitors like Mvasi and Zirabilis, with similar efficacy profiles. Market share is competitive, depending on formulary decisions.
2. What factors could accelerate Zirabev’s market penetration?
Physician acceptance, payer incentives, and favorable reimbursement policies are key accelerators.
3. Will prices drop further due to generic competition?
Yes. Increased biosimilar entry and absorption into standard care protocols exert downward pressure on prices.
4. How does FDA approval influence market prospects?
Approval provides market legitimacy, allowing Zirabev to compete directly with Avastin and other biosimilars.
5. What are the main barriers to Zirabev’s growth?
Brand loyalty, prescriber familiarity with Avastin, and payer preference for existing biosimilars limit immediate growth.
References
[1] IQVIA. (2022). Global and U.S. biosimilar market review.
[2] FDA. (2020). Zirabev (bevacizumab-bvzr) approval letter.
[3] EvaluatePharma. (2022). Oncology biologics and biosimilar market forecast 2022-2027.
Note: Data are estimations based on public market reports, FDA approvals, and industry sources.
